GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kiniksa Pharmaceuticals International PLC (NAS:KNSA) » Definitions » Price-to-Tangible-Book

KNSA (Kiniksa Pharmaceuticals International) Price-to-Tangible-Book : 3.91 (As of Mar. 26, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Kiniksa Pharmaceuticals International Price-to-Tangible-Book?

As of today (2025-03-26), Kiniksa Pharmaceuticals International's share price is $22.76. Kiniksa Pharmaceuticals International's Tangible Book per Share of Dec. 2024 for the quarter that ended in Dec. 2024 was $5.82. Hence, Kiniksa Pharmaceuticals International's Price to Tangible Book Ratio of today is 3.91.

The historical rank and industry rank for Kiniksa Pharmaceuticals International's Price-to-Tangible-Book or its related term are showing as below:

KNSA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.7   Med: 3.4   Max: 4.98
Current: 3.91

During the past 9 years, Kiniksa Pharmaceuticals International's highest Price to Tangible Book Ratio was 4.98. The lowest was 2.70. And the median was 3.40.

KNSA's Price-to-Tangible-Book is ranked worse than
72.34% of 846 companies
in the Drug Manufacturers industry
Industry Median: 2.26 vs KNSA: 3.91

A closely related ratio is called PB Ratio. As of today, Kiniksa Pharmaceuticals International's share price is $22.76. Kiniksa Pharmaceuticals International's Book Value per Sharefor the quarter that ended in Dec. 2024 was $6.05. Hence, Kiniksa Pharmaceuticals International's P/B Ratio of today is 3.76.


Kiniksa Pharmaceuticals International Price-to-Tangible-Book Historical Data

The historical data trend for Kiniksa Pharmaceuticals International's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiniksa Pharmaceuticals International Price-to-Tangible-Book Chart

Kiniksa Pharmaceuticals International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only 3.86 4.90 2.76 2.93 3.40

Kiniksa Pharmaceuticals International Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.93 3.37 3.17 4.29 3.40

Competitive Comparison of Kiniksa Pharmaceuticals International's Price-to-Tangible-Book

For the Drug Manufacturers - Specialty & Generic subindustry, Kiniksa Pharmaceuticals International's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kiniksa Pharmaceuticals International's Price-to-Tangible-Book Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kiniksa Pharmaceuticals International's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Kiniksa Pharmaceuticals International's Price-to-Tangible-Book falls into.



Kiniksa Pharmaceuticals International Price-to-Tangible-Book Calculation

Kiniksa Pharmaceuticals International's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Dec. 2024 )
=22.76/5.822
=3.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Kiniksa Pharmaceuticals International Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Kiniksa Pharmaceuticals International's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Kiniksa Pharmaceuticals International Business Description

Traded in Other Exchanges
N/A
Address
23 Old Bond Street, Floor 3, London, GBR, W1S 4PZ
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Executives
Mark Ragosa officer: Interim CFO C/O KINIKSA PHARMACEUTICALS CORP., 100 HAYDEN AVENUE, LEXINGTON MA 02421
Michael R Megna officer: Chief Accounting Officer 1050 HINGHAM STREET, ROCKLAND MA 02370
Eben Tessari officer: Chief Business Officer C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Sanj K Patel director, 10 percent owner, officer: Chairman & CEO C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Ross Moat officer: Group VP & Rilonacept GM C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
John Paolini officer: Chief Medical Officer C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Barry D Quart director C/O INTRABIOTICS PHARMACEUTICALS INC, 1009 OAK HILL ROAD, SUITE 201, LAFAYETTE CA 94549
Felix Baker director BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Julian Baker director BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667, director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Arian Pano officer: Chief Clinical Dev. Officer C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Thomas W. Beetham 10 percent owner, officer: Chief Legal Officer C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
G Bradley Cole director 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063